129 related articles for article (PubMed ID: 1452292)
1. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.
Kleinert HD; Stein HH; Boyd S; Fung AK; Baker WR; Verburg KM; Polakowski JS; Kovar P; Barlow J; Cohen J
Hypertension; 1992 Dec; 20(6):768-75. PubMed ID: 1452292
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.
Boyd SA; Fung AK; Baker WR; Mantei RA; Stein HH; Cohen J; Barlow JL; Klinghofer V; Wessale JL; Verburg KM
J Med Chem; 1994 Sep; 37(19):2991-3007. PubMed ID: 7932521
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs.
Wessale JL; Calzadilla SV; Boyd SA; Baker WR; Stein HH; Kovar PJ; Barlow J; Klinghofer V; Mantei R; Kleinert HD
J Cardiovasc Pharmacol; 1993 Oct; 22(4):644-52. PubMed ID: 7505369
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys.
Shibasaki M; Usui T; Inagaki O; Asano M; Takenaka T
J Pharm Pharmacol; 1994 Jan; 46(1):68-72. PubMed ID: 8201530
[TBL] [Abstract][Full Text] [Related]
5. Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
Ryan MJ; Hicks GW; Batley BL; Rapundalo ST; Patt WC; Taylor DG; Keiser JA
J Pharmacol Exp Ther; 1994 Jan; 268(1):372-9. PubMed ID: 8301578
[TBL] [Abstract][Full Text] [Related]
6. Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor.
Verburg KM; Polakowski JS; Kovar PJ; Klinghofer V; Barlow JL; Stein HH; Mantei RA; Fung AK; Boyd SA; Baker WR
J Cardiovasc Pharmacol; 1993 Jan; 21(1):149-55. PubMed ID: 7678671
[TBL] [Abstract][Full Text] [Related]
7. Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs.
McMahon EG; Yang PC; Babler MA; Bittner SE; Suleymanov OD; Cain-Janicki KJ; Bedell LJ; Hanson GJ; Cook CS
Hypertension; 1995 Jul; 26(1):95-100. PubMed ID: 7607739
[TBL] [Abstract][Full Text] [Related]
8. KRI-1314: an orally effective inhibitor of human renin.
Etoh Y; Miyazaki M; Saitoh H; Toda N
Jpn J Pharmacol; 1993 Sep; 63(1):109-19. PubMed ID: 8271523
[TBL] [Abstract][Full Text] [Related]
9. A novel nonpeptidic, orally active renin inhibitor.
Morishima H; Koike Y; Nakano M; Atsuumi S; Tanaka S; Funabashi H; Hashimoto J; Sawasaki Y; Mino N; Nakano M
Biochem Biophys Res Commun; 1989 Mar; 159(3):999-1005. PubMed ID: 2495004
[TBL] [Abstract][Full Text] [Related]
10. Ro 42-5892 is a potent orally active renin inhibitor in primates.
Fischli W; Clozel JP; el Amrani K; Wostl W; Neidhart W; Stadler H; Branca Q
Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
[TBL] [Abstract][Full Text] [Related]
11. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
12. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs.
Wessale JL; Kleinert HD; Calzadilla SV; Kovar PJ; Rosenberg SH
Am J Hypertens; 1993 Jun; 6(6 Pt 1):514-21. PubMed ID: 8343235
[TBL] [Abstract][Full Text] [Related]
13. Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs.
Blaine EH; Schorn TW; Boger J
Hypertension; 1984; 6(2 Pt 2):I111-8. PubMed ID: 6373590
[TBL] [Abstract][Full Text] [Related]
14. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
Denissen JF; Grabowski BA; Johnson MK; Boyd SA; Uchic JT; Stein H; Cepa S; Hill P
Drug Metab Dispos; 1994; 22(6):880-8. PubMed ID: 7895605
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
Shibasaki M; Asano M; Fukunaga Y; Usui T; Ichihara M; Murakami Y; Nakano K; Fujikura T
Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
[TBL] [Abstract][Full Text] [Related]
16. Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK-272 (SCO-272), a novel orally active renin inhibitor.
Ebihara T; Nishihara M; Takahashi J; Jinno F; Tagawa Y
Biopharm Drug Dispos; 2018 Mar; 39(3):175-183. PubMed ID: 29474740
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy.
Kleinert HD; Rosenberg SH; Baker WR; Stein HH; Klinghofer V; Barlow J; Spina K; Polakowski J; Kovar P; Cohen J
Science; 1992 Sep; 257(5078):1940-3. PubMed ID: 1411510
[TBL] [Abstract][Full Text] [Related]
18. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative].
Muneta S
Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates.
Coassolo P; Fischli W; Clozel JP; Chou RC
Xenobiotica; 1996 Mar; 26(3):333-45. PubMed ID: 8730924
[TBL] [Abstract][Full Text] [Related]
20. An orally active inhibitor of renin.
Pals DT; Thaisrivongs S; Lawson JA; Kati WM; Turner SR; DeGraaf GL; Harris DW; Johnson GA
Hypertension; 1986 Dec; 8(12):1105-12. PubMed ID: 3539793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
